With its booth, and scientific and social events, VSY Biotechnology was the center of attention at the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), the world’s premier ophthalmology event. VSY Biotechnology organized the Stars of Ophthalmology Award Ceremony, presented the awards to the finalists, and attracted a great deal of attention in Paris on September 14–18,
VSY Biotechnology invests in a faster and more efficient supply chain in Europe.
VSY Biotechnology, with head offices in the Netherlands, Spain, and Germany, has strengthened its network with new logistics centers in Europe. The company opened a new logistics center in Germany on 20 August 2019. A new online ordering system was commissioned at the beginning of the year.
VSY Biotechnology’s invention, the Rotaryjet Preloaded Injector containing an accessory system for the storage and injection of an intraocular lens, has been registered by the European Patent Institute (EPI). This newly patented technology minimises the use of viscoelastic material in intraocular lens implantation and provides ultimate ease of use.
The Rotaryjet Preloaded Injector,
ESCRS Board Member Prof.Dr. Ewa Mrukwa-Kominek told that Acriva Trinova implanted patients do not experience glare and halos and have very sharp visual equity.
Halos are bright circles that surround a light source, like headlights. Glare is light that enters your eye and interferes with your vision. These vision problems can be very disturbing even disabling after a cataract surgery.
VSY Biotechnology is now accepting applications for the Ophthalmology Star Awards.
The Stars of Ophthalmology will be selected among the applicants who have a scientific article published in an ophthalmology journal since January 2018.
The articles are required to be authored in English and already published in order to be eligible for the Ophthalmology Star Awards.
Offering its product scope to more than 60 countries from Germany to Japan, Brazil to South Korea, Spain to South Africa, VSY Biotechnology is still going on to take part in most of the world’s most important congresses. VSY Biotechnology participated in DOC 2019 which was held in Germany, Nuremberg Convention Center between May 23-25,
VSY Biotechnology announced the launch of its new sinusoidal trifocal IOL, AcrivaUD Trinova, at the 2017 European Society of Cataract and Refractive Surgeons meeting in Portugal. VSY has also confirmed that its patent applications have been submitted around the world, and its product CE mark was received in October 2017. AcrivaUD Trinova is the world’s first and only sinusoidal trifocal IOL manufactured with Sinusoidal Vision Technology (SVT).
VSY Biotechnology BV and Carl Zeiss Meditec AG jointly announced that both companies resolved their legal and patent disputes with respect to Tri-ED 611. The companies agreed not to disclose the terms of the settlement.
CEO Özge Altunbaş Göktekin of VSY Biotechnology, a significant global company in the field of ophthalmology, gave us valuable information on cataract disease and solutions provided by the company’s new trifocal intraocular lenses. Altunbaş said: “With the help of the trifocal intraocular lenses we developed, we can offer a solution for both cataracts and eye defects.
VSY Biotechnology CEO Özge Altunbaş Göktekin stated that extraordinary developments observed recently in science and communication technologies have caused a transformation in the management approaches adopted by companies and added: “With technological advances transforming management ideas and approaches in enterprises, managers and employees now feel obliged to adopt a proactive, creative, and responsible role in their organization.”
We addressed our questions to VSY Biotechnology CEO Özge Altunbaş Göktekin about changing management approaches.